China Approves novel homegrown flu treatment, Onradivir

BEIJING: China's top drug regulator has approved a new homegrown flu treatment, onradivir, marking a significant addition to the global fight against influenza. This first-in-class innovative medicine targets a novel protein and is authorized for treating adult patients with uncomplicated influenza A.
The National Medical Products Administration announced the approval, stating that "The approval of this medication provides patients with a new treatment option."
Onradivir was jointly developed by Raynovent in Guangzhou, Guangdong province, the First Affiliated Hospital of Guangzhou Medical University, and leading respiratory disease research institutions.
According to China Daily, this medicine is the world's first anti-influenza drug to target the PB2 protein of the virus's RNA polymerase. Its developers claim the new medicine offers "rapid, potent and low-resistance efficacy," presenting a "Chinese solution to tackling global influenza epidemics."
Globally, influenza accounts for approximately 1 billion cases annually, including 3 to 5 million severe cases and an estimated 290,000 to 650,000 deaths each year.
Comments
Post a Comment